Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer

Y-mAbs Therapeutics (NASDAQ:YMAB - Free Report) had its target price cut by Oppenheimer from $20.00 to $15.00 in a research report released on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

YMAB has been the subject of several other research reports. Bank of America cut shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a research note on Tuesday, April 22nd. Wedbush reiterated an "outperform" rating and set a $18.00 target price (down previously from $21.00) on shares of Y-mAbs Therapeutics in a research note on Wednesday. Truist Financial lowered their target price on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Morgan Stanley lowered their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research note on Wednesday, March 5th. Finally, HC Wainwright lowered their target price on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $15.60.

Y-mAbs Therapeutics Stock Down 0.8%

Shares of YMAB traded down $0.04 during trading hours on Thursday, reaching $4.71. 253,129 shares of the company traded hands, compared to its average volume of 310,963. Y-mAbs Therapeutics has a 12-month low of $3.55 and a 12-month high of $16.11. The stock has a market capitalization of $213.29 million, a P/E ratio of -8.72 and a beta of 0.53. The business has a fifty day moving average price of $4.37 and a 200-day moving average price of $6.38.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.10. The company had revenue of $20.90 million for the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. As a group, research analysts predict that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Insider Buying and Selling at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of the company's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now owns 202,721 shares of the company's stock, valued at approximately $1,060,230.83. This represents a 5.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 22.50% of the company's stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN increased its position in Y-mAbs Therapeutics by 54.1% during the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock worth $137,000 after purchasing an additional 6,131 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Y-mAbs Therapeutics by 10.4% in the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company's stock worth $399,000 after acquiring an additional 2,854 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Y-mAbs Therapeutics by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 822,309 shares of the company's stock worth $6,440,000 after acquiring an additional 8,820 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Y-mAbs Therapeutics by 1.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company's stock worth $2,228,000 after acquiring an additional 4,963 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Y-mAbs Therapeutics in the fourth quarter valued at $46,000. Hedge funds and other institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.